[go: up one dir, main page]

IL151566A0 - Stepwise alkylation of 5-substituted 1-(4-fluorophenyl)-1,3-dihydroisobenzofurans - Google Patents

Stepwise alkylation of 5-substituted 1-(4-fluorophenyl)-1,3-dihydroisobenzofurans

Info

Publication number
IL151566A0
IL151566A0 IL15156601A IL15156601A IL151566A0 IL 151566 A0 IL151566 A0 IL 151566A0 IL 15156601 A IL15156601 A IL 15156601A IL 15156601 A IL15156601 A IL 15156601A IL 151566 A0 IL151566 A0 IL 151566A0
Authority
IL
Israel
Prior art keywords
dihydroisobenzofurans
fluorophenyl
substituted
stepwise alkylation
alkylation
Prior art date
Application number
IL15156601A
Other languages
English (en)
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of IL151566A0 publication Critical patent/IL151566A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/10—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/08—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D277/10—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Furan Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrane Compounds (AREA)
IL15156601A 2000-03-13 2001-03-09 Stepwise alkylation of 5-substituted 1-(4-fluorophenyl)-1,3-dihydroisobenzofurans IL151566A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200000403 2000-03-13
DKPA200000414 2000-03-14
PCT/DK2001/000159 WO2001068629A1 (en) 2000-03-13 2001-03-09 Stepwise alkylation of 5-substituted 1-(4-fluorophenyl)-1,3-dihydroisobenzofurans

Publications (1)

Publication Number Publication Date
IL151566A0 true IL151566A0 (en) 2003-04-10

Family

ID=26068792

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15156601A IL151566A0 (en) 2000-03-13 2001-03-09 Stepwise alkylation of 5-substituted 1-(4-fluorophenyl)-1,3-dihydroisobenzofurans

Country Status (22)

Country Link
US (2) US6864379B2 (is)
EP (1) EP1265881A1 (is)
JP (1) JP2003527385A (is)
KR (1) KR20020080485A (is)
CN (1) CN1427835A (is)
AU (1) AU2001239210A1 (is)
BG (1) BG107046A (is)
BR (1) BR0109364A (is)
CA (1) CA2402553A1 (is)
CZ (1) CZ20023100A3 (is)
EA (1) EA200200968A1 (is)
HR (1) HRP20020758A2 (is)
HU (1) HUP0300273A2 (is)
IL (1) IL151566A0 (is)
IS (1) IS6530A (is)
MX (1) MXPA02008684A (is)
NO (1) NO20024352L (is)
NZ (1) NZ521204A (is)
PL (1) PL357022A1 (is)
SK (1) SK14522002A3 (is)
TR (1) TR200202195T2 (is)
WO (1) WO2001068629A1 (is)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100604156B1 (ko) * 1999-04-14 2006-07-25 하. 룬트벡 아크티에 셀스카브 시탈로프람의 제조방법
NL1017417C1 (nl) 2000-03-03 2001-03-16 Lundbeck & Co As H Werkwijze voor de bereiding van Citalopram.
NL1017500C1 (nl) 2000-03-13 2001-04-26 Lundbeck & Co As H Werkwijze voor de bereiding van Citalopram.
AR032455A1 (es) 2000-05-12 2003-11-12 Lundbeck & Co As H Metodo para la preparacion de citalopram, un intermediario empleado en el metodo, un metodo para la preparacion del intermediario empleado en el metodo y composicion farmaceutica antidepresiva
PL368452A1 (en) * 2001-11-08 2005-03-21 Sepracor, Inc. Methods for treating depression and other cns disorders using enantiomerically enriched desmethyl- and didesmethyl-metabolites of citalopram
US7078541B2 (en) * 2002-02-07 2006-07-18 Galileo Pharmaceuticals, Inc. Benzofuran derivatives
TWI306846B (en) 2002-08-12 2009-03-01 Lundbeck & Co As H Method for the separation of intermediates which may be used for the preparation of escitalopram
AU2003223105A1 (en) * 2003-03-24 2004-10-18 Hetero Drugs Limited Novel crystalline forms of (s)-citalopram oxalate
US20090018351A1 (en) * 2003-11-12 2009-01-15 Dr. Reddy's Laboratories, Inc. Preparation of escitalopram
TWI339651B (en) 2004-02-12 2011-04-01 Lundbeck & Co As H Method for the separation of intermediates which may be used for the preparation of escitalopram
US7932081B2 (en) * 2005-03-10 2011-04-26 Gen-Probe Incorporated Signal measuring system for conducting real-time amplification assays

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1143703A (is) * 1965-03-18
GB1526331A (en) * 1976-01-14 1978-09-27 Kefalas As Phthalanes
GB8419963D0 (en) * 1984-08-06 1984-09-12 Lundbeck & Co As H Intermediate compound and method
GB8814057D0 (en) * 1988-06-14 1988-07-20 Lundbeck & Co As H New enantiomers & their isolation
US5296507A (en) * 1990-09-06 1994-03-22 H.Lundbeck A/S Treatment of cerbrovascular disorders
DE19626659A1 (de) * 1996-07-03 1998-01-08 Basf Ag Verfahren zur Herstellung von Phthaliden
DE19627697A1 (de) * 1996-07-10 1998-01-15 Basf Ag Verfahren zur Herstellung von Phthaliden
SK283309B6 (sk) 1997-07-08 2003-05-02 H. Lundbeck A/S Spôsob výroby citalopramu a medziprodukty
UA62985C2 (en) * 1997-11-10 2004-01-15 Lunnbeck As H A method for the preparation of citalopram
ES2149734T3 (es) 1997-11-11 2003-02-16 Lundbeck & Co As H Metodo para la preparacion de citalopram.
WO2000023431A1 (en) * 1998-10-20 2000-04-27 H. Lundbeck A/S Method for the preparation of citalopram
EP1140886B1 (en) * 1998-12-23 2003-04-02 H. Lundbeck A/S Method for the preparation of 5-cyanophthalide
AR022329A1 (es) * 1999-01-29 2002-09-04 Lundbeck & Co As H Metodo para la preparacion de 5-cianoftalida
KR100604156B1 (ko) 1999-04-14 2006-07-25 하. 룬트벡 아크티에 셀스카브 시탈로프람의 제조방법
ITMI991581A1 (it) 1999-06-25 2001-01-15 Lundbeck & Co As H Metodo per la preparazione di citalopram
ITMI991579A1 (it) * 1999-06-25 2001-01-15 Lundbeck & Co As H Metodo per la preparazione di citalopram
EP1228056B1 (en) * 1999-10-25 2004-09-22 H. Lundbeck A/S Method for the preparation of citalopram
US6310222B1 (en) * 1999-11-01 2001-10-30 Sumika Fine Chemicals Co., Ltd. Production method of 5-phthalancarbonitrile compound, intermediate therefor and production method of the intermediate
AR026063A1 (es) * 1999-11-01 2002-12-26 Lundbeck & Co As H Metodo para la preparacion de 5-carboxiftalida.
CN1398263A (zh) 1999-12-28 2003-02-19 H·隆德贝克有限公司 制备西酞普兰的方法
HK1052512B (zh) 1999-12-30 2006-03-03 H. 隆德贝克有限公司 西酞普兰的制备方法
PL197821B1 (pl) 2000-01-14 2008-04-30 Lundbeck & Co As H Sposób wytwarzania 5-cyjanoftalidu
IT1317729B1 (it) * 2000-01-18 2003-07-15 Norpharma S P A Procedimento per la preparazione della 5-carbossiftalide.
US6433196B1 (en) * 2000-02-17 2002-08-13 Sumika Fine Chemicals Co., Ltd. Production method of citalopram, intermediate therefor and production method of the intermediate
NL1017415C1 (nl) * 2000-02-24 2001-05-18 Lundbeck & Co As H Werkwijze voor de bereiding van Citalopram.
IES20010143A2 (en) 2000-02-24 2001-07-25 Lundbeck & Co As H Method for the preparation of citalopram
NL1017417C1 (nl) * 2000-03-03 2001-03-16 Lundbeck & Co As H Werkwijze voor de bereiding van Citalopram.
GB0005477D0 (en) 2000-03-07 2000-04-26 Resolution Chemicals Limited Process for the preparation of citalopram
NL1017500C1 (nl) * 2000-03-13 2001-04-26 Lundbeck & Co As H Werkwijze voor de bereiding van Citalopram.
TR200202166T2 (tr) * 2000-03-13 2002-12-23 H. Lndbeck A/S Sitalopramın preparasyon metodu
PT1265882E (pt) 2000-03-14 2004-06-30 Lundbeck & Co As H Metodo para preparacao de citalopram; composto e citalopram
HUP0300134A2 (en) 2000-03-16 2003-05-28 Lundbeck & Co As H Method for the preparation of 5-cyano-1-(4-fluorophenyl)-1,3-dihydroisobenzofurans
AR032455A1 (es) 2000-05-12 2003-11-12 Lundbeck & Co As H Metodo para la preparacion de citalopram, un intermediario empleado en el metodo, un metodo para la preparacion del intermediario empleado en el metodo y composicion farmaceutica antidepresiva
EA200200332A1 (ru) 2000-07-06 2002-06-27 Х.Лундбекк А/С Способ получения циталопрама
IL144817A0 (en) * 2000-08-18 2002-06-30 Lundbeck & Co As H Method for the preparation of citalopram
IL147226A (en) * 2000-12-22 2006-04-10 Lundbeck & Co As H Process for the preparation of pure citalopram
SK284418B6 (sk) 2000-12-28 2005-04-01 H. Lundbeck A/S Spôsob výroby citalopramu

Also Published As

Publication number Publication date
NO20024352D0 (no) 2002-09-12
IS6530A (is) 2002-08-27
TR200202195T2 (tr) 2002-12-23
KR20020080485A (ko) 2002-10-23
JP2003527385A (ja) 2003-09-16
US20050020670A1 (en) 2005-01-27
US20030083509A1 (en) 2003-05-01
CA2402553A1 (en) 2001-09-20
CN1427835A (zh) 2003-07-02
US6864379B2 (en) 2005-03-08
BR0109364A (pt) 2002-12-24
CZ20023100A3 (cs) 2003-02-12
PL357022A1 (en) 2004-07-12
HUP0300273A2 (hu) 2003-06-28
AU2001239210A1 (en) 2001-09-24
WO2001068629A1 (en) 2001-09-20
MXPA02008684A (es) 2003-02-24
SK14522002A3 (sk) 2003-03-04
HRP20020758A2 (en) 2004-12-31
NO20024352L (no) 2002-10-08
NZ521204A (en) 2004-03-26
EA200200968A1 (ru) 2003-02-27
EP1265881A1 (en) 2002-12-18
BG107046A (en) 2003-05-30

Similar Documents

Publication Publication Date Title
AP2003002836A0 (en) 3-(4-Amidopyrrol-2-ylmethlidene)-2-indolinone derivatives as protein kinase inhibitors.
TWI317634B (en) Aroyl indoles compounds
MXPA03006250A (es) Compuestos heterociclicos terapeuticos.
IL158784A0 (en) Substituted 2-pyridine-cyclohexane-1,4-diamine derivatives
GB0203654D0 (en) Secure network access
MXPA03002297A (es) Compuestos de triazol utiles como inhibidores de proteina cinasa.
BR9915534B1 (pt) 1-piridil substituìdo)-1,2,4-triazóis inseticidas.
EP1172112B8 (en) Preventive, alleviative or remedy for hypertension
IL151566A0 (en) Stepwise alkylation of 5-substituted 1-(4-fluorophenyl)-1,3-dihydroisobenzofurans
AU2001280590A1 (en) 5-substituted 2-aryl-4-pyrimidinones
ZA200206808B (en) Endoparasiticidal gel composition.
PL360115A1 (en) Method for the preparation of 5-cyano-1-(4-fluorophenyl)-1,3-dihydroisobenzofurans
ZA200205982B (en) Endoparasiticidal agents.
IL146531A0 (en) 5-substituted arylpyrimidines
PL370715A1 (en) [1.2]-oxazin-3,5-diones
AU2003222435A8 (en) Process for the preparation of 1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)- 1,3-dihydro-5-isobenzofuran carbonitrile
MXPA03006970A (es) Nuevo uso de iloperidona.
AR027974A1 (es) 1-aril-ciclopropilmetilamino-1,3,5-triazinas substituidas
IL164377A (en) Methods of preparation of 2-(7-chloro-1,8-naphthyridine-2yl)-3-(5-methyl-2-oxo-hexyl)-1-isoindolinone
ITGE20010009A0 (it) Inserto emisferico per frese.
GB0124067D0 (en) Dual reamer
AU2001272543A1 (en) 1-alkyl-3-(1-(substituted phenyl) benzotriazol-6-yl) uracils
IL152086A0 (en) Secure document access system
ZA200301399B (en) Chemokine receptor binding heterocyclic compounds.
HU2091U (en) Collar-closing wedge